Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Nicholas Short, MD, on his hopes for the new year in blood cancer.
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Augment 101 is phase I/II trial investigating revumenib in patients with MLL rearranged or mNPM1 acute leukemias.
Eprenetapopt and azacitidine after allogeneic HSCT was well tolerated in patients with TP53-mutated AML and MDS.
Baseline genetic characteristics are the primary determinants of allogeneic HSCT outcomes in older adults with AML.
Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022
Marina Konopleva, MD, PhD, discusses her new role at the Albert Einstein College of Medicine and highlights from her career ...
Gilteritinib plus induction and consolidation chemotherapy demonstrated acceptable safety outcomes and efficacy in patients ...
Dr. Konopleva spoke to Blood Cancers Today during the 2022 SOHO Annual Meeting.
The efficacy of enasidenib in patients with AML depends on the mutation type.
A conditioning regimen of clofarabine plus total body irradiation prior to allogeneic hematopoietic stem cell transplantation ...
New research suggests venetoclax-containing regimens with intensive treatment and allogeneic hematopoietic stem cell ...
Guillermo Garcia-Manero, MD, gives his perspective.
Wei Wang, MD, PhD, and colleagues conducted the study and published its findings in Cancers.
A second allogeneic hematopoietic stem cell transplantation (HSCT) is a reasonable treatment option for patients with ...
The report showed significant demographic and geographic imbalances in pivotal clinical trials leading to drug approval.
DSP-5336 is an investigational small-molecule inhibitor against the binding of menin and mixed-lineage leukemia protein.
A phase II, multicenter, open-label trial found that eprenetapopt plus azacitidine was well tolerated and safe.
The trial examined selinexor's effect on treatment outcomes in patients with AML and high-risk MDS.
The global, phase III PANTHER trial investigated the comparison in higher-risk MDS, higher-risk CMML, and AML.
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Assistant Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Advertisement
670 Madison Ave.
Manalapan, NJ 07726
© 2022 Mashup Media, LLC. All rights reserved.